

### **REMARKS**

Entry of the foregoing, reexamination and reconsideration of the above-identified application are respectfully requested and believed to be in order.

#### **Examiner Interview**

Applicants note with appreciation the courtesies extended by Examiners Kim and Lankford in the personal interview of September 17, 2008. During the interview, the patentability of the instant claims over the cited prior art was discussed. One of the inventors, Dr. Steven Pakola, presented information showing the differences in activities of plasmin versus microplasmin. In addition, information regarding ongoing clinical trials involving the product claimed herein was also presented. The information presented was favorably considered by the Examiners. No agreement was reached, however, and applicants noted that the substance of the subject matter presented would be presented in this response.

#### **Rejection of Record**

Claims 57-61, 64-69, 71, 72 and 80-87 have been rejected under 35 U.S.C. §103(a) as allegedly being unpatentable over Trese et al (USP 5,304,118) in view of Collen et al (WO 2002/50290) in further view of Wu et al (USP 4,774,087). Claims 57, 63, 66 and 70 have been rejected under 35 U.S.C. §103(a) as allegedly being unpatentable over Trese et al (USP 5,304,118) in view of Collen et al (WO 2002/50290) in further view of Wu et al (USP 4,774,087) and Tanaka et al. 2000 (Sem Ophthalmol 15, 51). These rejections are respectfully traversed.

The rejection of the claims over these references has been maintained and repeated from the prior Official Action. The Official Action asserts that microplasmin allegedly is an art-recognized equivalent of, or a suitable alternative to, plasmin. More specifically, the question raised, and the basis for the rejection, is “whether microplasmin has the same activity (i.e. serine protease activity) for the same purpose (i.e. vitreolysis) as plasmin does.” (Official Action at 3). The Official Action alleges that “the” same activity “is drawn to functional and structural characteristics shared by plasmin and microplasmin,” and that “plasmin and microplasmin both possess fibrinolytic activity (same activity) and they have the identical domain/sequence for such activity, and because of such similarity they can be used for the same purpose of vitreolysis (lysis of collagen)” (emphasis

added). (*Id.*) On this basis, the Official Action concludes that “microplasmin and plasmin are considered to be art-accepted equivalent”, or that “microplasmin is a suitable alternative to plasmin.” (*Id.* at 3-4.)

Applicant respectfully disagrees with these assertions. First of all, these assertions narrow the proposed concept of “same activity” (entailing functional and structural characteristics) to the function and structure shared by microplasmin and plasmin, i.e. the catalytic domain. This overlooks and ignores the structural differences that exist between microplasmin and plasmin, *i.e.*, the absence of the 5 kringle domains comprised in the regulatory chain of plasmin and related changes in actual activity of the catalytic domain due to associated alteration in 3-dimensional structure of the molecule. The absence of these kringle regulatory domains has a profound effect on the function of the catalytic chain. Reducing alleged equivalency between microplasmin and plasmin to an argument based on what both molecules share is only half the story. One skilled in the art would also focus on the functional consequences of structural features that both molecules don't share (structural difference). To do otherwise, is an oversimplified and much too narrow view on microplasmin versus plasmin. Such a focus would be employing hindsight in alleging that the use of microplasmin would have been obvious in view of prior work with plasmin. This approach would be in error. Therefore, and for the reasons outlined hereafter, applicant strongly disagrees with the alleged equivalency between microplasmin and plasmin, as well as with the fact that microplasmin would *a priori* be a suitable alternative to plasmin. Either view can only be arrived at using improper hindsight analysis. *See*, Declaration under 37 C.F.R. §1.132 of Steve Pakola, M.D. (“Pakola Declaration”), ¶6, submitted herewith.

As introduction, applicant first wishes to refresh the picture of the eye's components that are important in view of the invention. In the vitreous of a normal eye, collagen fibers run from the anterior to the posterior pole of the eye, as well as parallel with the internal limiting membrane/lamina (ILM or ILL). Together with other macromolecules such as glucosaminoglycans (e.g. chondroitin, hyaluronan) and other proteins (e.g. fibrillin-containing microfibrils, fibronectin, opticin), collagen fibers are believed to provide the gelatinous strength to the vitreous. Although collagen fibers naturally tend to stick together they are kept apart from each other in the vitreous. Liquefaction of the vitreous disrupts the network between collagen fibers and

other vitreous components and causes collapse of (parts of) the vitreous. The vitreous components are linked to the ILM (an extracellular matrix lining the inner retina). The ILM contains proteoglycans, fibronectin, laminin and different types of collagen (e.g. types I and IV). Laminin and fibronectin are considered to be major ILM-components responsible for gluing the vitreous to the ILM. During the process of posterior vitreous detachment (PVD) the linkage between vitreous and ILM is gradually lost, and eventually the vitreous becomes completely detached from the posterior part of the macula/retina. More information about these aspects of the eye can be found in, e.g., Bishop 2000 (Prog Retin Eye Res 19, 323), Sebag & Balazs 1989 (Invest Ophthalmol Vis Sci 30, 1867) and Sebag 2005 (Trans Am Ophthalmol Soc 103, 473). *See*, Pakola Declaration, ¶7.

As noted by Dr. Pakola, a skilled person will appreciate that the efficacy and safety of a protease for inducing vitreolysis (vitreous liquefaction and/or posterior vitreous detachment) depends on a multitude of (not necessarily mutually exclusive) factors as discussed in detail herein. *See*, Pakola Declaration, ¶8.

*i) Accessibility of protease substrates*

Factors determining the accessibility to its substrates by a protease include the size of the protease (influencing e.g. diffusion and steric hindrance) and binding/immobilization of the protease by proteins (not necessarily substrate proteins) through, e.g., non-catalytic sites on the protease (influencing sequestration of the protease as well as its diffusion). *See*, Pakola Declaration, ¶9.

When applying this factor to microplasmin and plasmin, the patent application describes in paragraph [0081] that microplasmin is a molecule of 26.5 to 29 kDa consisting essentially of the catalytic domain plus a number of amino acid residues from the C-terminus of the regulatory chain but excluding all 5 kringle domains of the regulatory chain as present in plasmin, a molecule of 65 to 83 kDa. *See*, Pakola Declaration, ¶10.

Moser et al. 1993 (J Biol Chem 268, 18917) and Stack et al. 1992 (Biochem J 284, 103) describe the binding properties of parts of the plasminogen molecule with proteins (or fragments thereof) which occur in the eye: fibronectin, laminin and collagen IV. The plasmin fragments studied were (i) a fragment spanning kringles 1, 2 and 3 (hereafter "K1-3"), a fragment spanning

kringle 4 (hereafter "K4"), and miniplasminogen (kringle 5 + catalytic domain); kringle domains are known to contain lysine-binding sites. Whereas K1-3 and K4 bind fibronectin and collagen IV, miniplasminogen (and, hence, also microplasminogen which lacks kringle 5) does not bind to these proteins. All of K1-3, K4 and miniplasminogen bind to laminin, but binding of miniplasminogen is mainly effectuated through kringle 5; the binding of the catalytic domain (such as in microplasmin) is lysine-independent. *See*, Pakola Declaration, ¶11.

The difference in structure between microplasmin and plasmin thus affects the biological properties of the molecules. There is a significant difference between microplasmin and plasmin with regard to their binding to at least the eye proteins fibronectin, laminin and collagen IV. Whereas plasmin binds to all (thus bringing the catalytic domain in close contact with the substrate), microplasmin is potentially binding only to laminin. This difference is due to the difference in structure and lack of kringle domains in microplasmin. *See*, Pakola Declaration, ¶12.

The significantly decreased sequestration of microplasmin (vs plasmin) by eye proteins is reasonably expected to increase its diffusion throughout the vitreous and ILM. On the other hand, microplasmin is about 1/3 of the size of plasmin which is also reasonably expected to contribute to increased diffusion of microplasmin (vs plasmin). Both aspects raise concerns about the to be expected efficacy of microplasmin in vitreolysis as more and/or other targets (relative to plasmin) may be available for proteolytic degradation. Safety concerns also raise as the chances for microplasmin to reach the retinal cells is significantly increased due to its smaller size, and it should be kept in mind that plasmin, when having access to membranes, is disrupting these membranes and is causing cell lysis (Okajima et al. 1995 – J Lab Clin Med 126, 377). *See*, Pakola Declaration, ¶13.

Hence, the structural differences between microplasmin and plasmin are reasonably expected to significantly change the efficacy with which eye substrates are proteolytically degraded and warrants very careful monitoring of microplasmin's safety when applied for vitreolysis. The structural and enzymatic properties, and the effect of the structural properties on the enzymatic properties of plasmin apparently make it a safe and efficient protease for pharmacologic vitreolysis. Safety and efficacy of microplasmin for pharmacologic vitreolysis can, however, not *a priori* be established in view of the perturbed balance (relative to plasmin) between catalytic activity *per se*

and the influence of the structural changes (lack of kringle regulatory chain) on the catalytic activity, in particular on the *in situ* catalytic activity. See, Pakola Declaration, ¶14.

Previously the applicant provided evidence for differences in the *in vitro* catalytic activity between microplasmin and plasmin (see, Declaration of Dr. Steve Pakola Under 37 C.F.R. §1.132, submitted February 11, 2008). This work has been extended to comparing the action of microplasmin and plasmin on *ex-vivo* human vitreous. See, Pakola Declaration, ¶15. Vitreous was removed from human eyes and digested with microplasmin and plasmin. After digestion samples were separated on an SDS-PAGE gel followed by Western blot analysis of fibrinogen (Figure 1 in Appendix A of Declaration under 37 C.F.R. §1.132 of Steve Pakola, M.D.)<sup>1</sup> and MMP-9 (Figure 2 in Appendix A).

Figure 1 confirms the earlier reported *in vitro* results in that plasmin more efficiently degrades fibrinogen than does microplasmin. The differences for MMP-9 (Figure 2) are even more striking. The control sample (no plasmin or microplasmin added to the *ex-vivo* human vitreous) shows bands of over 260 kDa (presumed multimer of (pro)-MMP9), of around 210 kDa (pro-MMP9 homodimer size reported to be ca. 215 kDa) and of around 52 kDa (size of inactive MMP-9 reported to be ca. 50-60 kDa). The sample digested with microplasmin shows a very prominent new band of about 82 kDa, which corresponds to the reported size of activated MMP-9 (ca. 82 kDa). This band seems completely absent in the sample digested with plasmin where new bands occur with a size of ca. 65 kDa (which could correspond to activated MMP-9 from which the C-terminal hemopexin-like domain is removed). Overall, the differences detected with an anti-MMP-9 antibody between microplasmin- and plasmin-digested *ex-vivo* human vitreous are striking and very significant. The reports on MMP-9 are by Goldberg et al. 1992 (J Biol Chem 267, 4583) and by Shapiro et al. 1995 (J Biol Chem 270, 6351). See, Pakola Declaration, ¶16.

As stated by Dr. Pakola:

The above observations on *ex-vivo* human vitreous clearly and unequivocally show the non-equivalency of microplasmin and plasmin. In addition, knowing that the ubiquitous vitreous/ILM-component collagen IV is degraded by MMP-9, and given the as yet unknown downstream effect of microplasmin on MMP-9 compared to

---

<sup>1</sup> All references to "Appendix A" made herein are referring to Appendix A of Declaration under 37 C.F.R. §1.132 of Steve Pakola, M.D..

plasmin, it cannot *a priori* be established that microplasmin is a suitable alternative to plasmin for the purpose of vitreolysis. Microplasmin would not be assumed an equivalent of plasmin given the unpredictability of the effect of microplasmin *in vivo* in light of the significant differences in enzymatic activity and binding characteristics between the two molecules. These differences are evident from *in vitro* assessment.

Pakola Declaration, ¶17.

Contrary to the assertions in the Official Action, the activity of microplasmin would not have been expected based upon the knowledge of plasmin. The unpredictability in the *in vivo* setting is dramatically magnified. In the actual setting of pharmacologic vitreolysis, there are various substrates that are important in determining the effect of a pharmacologic vitreolytic agent. These substrates also have different relative importance in the vitreous or the vitreoretinal interface, further complicating the ability to translate any differences in enzymatic activity and binding characteristics observed in testing to actual effect in the relevant clinical setting of pharmacologic vitreolysis in terms of either safety or efficacy. The impact of dramatically different size and binding characteristics on downstream effects of microplasmin and plasmin *in vivo* could not have been predicted prior to the invention. In addition, the differential diffusion and localization of the drug due to dramatically different size and binding characteristics make its effect in the complex biologic system of the vitreous and vitreoretinal interface unpredictable. *See*, Pakola Declaration, ¶18.

Rather than render obvious the claimed invention, the one skilled in the art would be led away from the use of microplasmin:

Those limited aspects that can be hypothesized actually would teach *against* use of microplasmin relative to plasmin, due to safety concerns over greater diffusion through the ILM and into the retina, due to 1) the greater digestion of the collagen type IV in the ILM, 2) the smaller size of the molecule, and 3) the lack of binding sites including to  $\alpha 2$ -antiplasmin to retain and/or metabolize the molecule in the vitreous.

*See*, Pakola Declaration, ¶19.

(ii) *The spectrum of protease activity*

A number of serine proteases and other broad-spectrum proteases have been evaluated for their suitability in inducing vitreolysis. Serine proteases include trypsin, chymotrypsin and subtilisin. Other broad-spectrum proteases include dispase. These proteases are not without serious adverse effects. Trypsin was reported to cause complete detachment of the ILM from the retina (Hara 1994 – Jpn J Ophthalmol 38, 375), something not wanted in the clinic. Chymotrypsin was reported to destroy the posterior capsule of the lens and to lead to cataract development (Laryukhina & Ziangirova 1977 – Vestn Oftalmol (6), 77) and subtilisin (nattokinase, Takano et al. 2006 – Invest Ophthalmol Vis Sci 47, 2075), being a bacterial protein, has the potential drawback of inducing unwanted immune reactions. Dispace, slightly larger than microplasmin (35.9 to 41 kDa compared to 26.5-29 kDa for microplasmin), has a protease spectrum at least partially overlapping with that of microplasmin: fibronectin and collagen IV are good substrates for dispase. Nevertheless, dispase was reported to exert toxic effects on the retina (Jorge et al. 2003 – Curr Eye Res 26, 107). It is moreover a bacterial protein, thus potentially inducing unwanted immune reactions. In view of the safety issues observed with proteases structurally different from, but sharing the catalytic activity of plasmin, the Examiner's allegation as if microplasmin were an equivalent of or a suitable alternative to plasmin based on the shared serine protease activity is an oversimplified view on the reality of vitreolysis in the eye. *See*, Pakola Declaration, ¶20.

As noted by Dr. Pakola, plasmin and microplasmin, like many, many proteases, can lyse collagen to some degree. However, the vitreous (the key site of interest for liquefaction) is composed of numerous other substrates that can be modulated differently. Further, the vitreoretinal interface (the key site of interest for induction of posterior vitreous detachment) has different concentrations of various substrates than are present in the vitreous. Further, there are certain substrates of proteases, including MMPs such as collagenase, that once activated have their own downstream effect on vitreous and vitreoretinal interface. *See*, Pakola Declaration, ¶21.

The broad-spectrum protease activity of microplasmin is reported even after the publication of the instant invention to be of concern relative to safety and efficacy, and a combination of several more specific enzymes is suggested:

“Indeed, broad acting agents, such as microplasmin, may have a higher likelihood of inducing both a breakdown in vitreous macromolecules and vitreoretinal separation. However, there may also

be untoward side effects if the agent's action is too broad. ... Thus, rather than employing a single broad-acting substance such as microplasmin or dispase, a combination of highly specific agents, such as collagenase, hyaluronidase, or chondroitase, may be safer and more effective." (Sebag 2005 – Trans Am Ophthalmol Soc 103, 473; see page 489, last 9 lines of 5<sup>th</sup> full paragraph).

See, Pakola Declaration, ¶22.

(iii) *The kinetics of protease activity.*

The kinetics of protease activity influences the efficiency of substrate degradation. This process, however, competes with the kinetics of autodegradation of the protease (especially in case of broad-spectrum proteases), as well as with the kinetics of inhibition of the protease by endogenous protease inhibitors. As outlined previously, subtle but complex differences exist between microplasmin and plasmin in *in vitro* degradation of protein substrates present in the eye. As described under (i), this was confirmed by work extending to ex-vivo human vitreous (fibrinogen and MMP-9). To what extent these findings can be extrapolated to the more complex true in situ situation is unpredictable and a priori raises concerns about the safety and efficacy of microplasmin as compared to plasmin for the purpose of vitreolysis. See, Pakola Declaration, ¶23.

Applicant has also previously reported (see Declaration of Dr. Steve Pakola Under 37 C.F.R. §1.132, submitted February 11, 2008) that microplasmin is inhibited much slower by antiplasmin than plasmin.

Included in the Pakola Declaration submitted herewith is an analysis of *ex-vivo* human vitreous for the presence of antiplasmin by means of Western blotting and this inhibitor is clearly present in the human vitreous (see Figure 3 in Appendix A). See, Pakola Declaration, ¶25.

As noted by Dr. Pakola, the previously and currently presented *in vitro* and *ex-vivo* data demonstrate a plethora of differences in action between microplasmin and plasmin. These differences make it *a priori* unpredictable whether the action of microplasmin for the purpose of vitreolysis would be as safe and efficient as plasmin's action. In preparing for clinical trials with microplasmin for vitreolysis, the applicant performed preclinical studies on human post-mortem eyes (in addition to the preclinical studies on feline eyes and on pig post-mortem eyes already described in the instant patent application) and demonstrated a dose-dependent microplasmin-



induced pharmacologic vitreolysis without damaging the underlying retinal tissue/cells, as is illustrated in Figure 4 (in Appendix A). *See*, Pakola Declaration, ¶26.

The benefits of microplasmin have been recognized. In view of the encouraging results, microplasmin had proceeded into clinical trials, the largest of these trials to date involving 125 patients (1 eye/patient) without PVD but eligible for surgical vitrectomy (29 receiving 25 µg microplasmin/eye; 33 receiving 75 µg microplasmin/eye; 32 receiving 125 µg microplasmin/eye; and 31 receiving an equal volume of saline placebo/eye). A dose-dependent improvement, with best response at the highest microplasmin dose, was observed for a number of clinically relevant endpoints, one of them being the resolution of macular holes without the need of additional surgical vitrectomy. Where none of the eyes of the 15 patients with macular holes and receiving placebo displayed closure of macular holes, such closure was observed in the eyes of 7 out of the 20 patients with macular holes and receiving 125 µg/eye. Closure of macular holes without surgical vitrectomy was also observed in eyes of patients receiving 25µg or 75µg microplasmin/eye, albeit at lower frequency. An illustration of microplasmin-induced closure of a macular hole is given in Figure 5 (in Appendix A). This finding is considered a potentially groundbreaking advance for treatment of these patients, given that there is no available treatment for these patients other than major, invasive eye surgery (vitrectomy) and the risks associated therewith. *See*, Pakola Declaration, ¶27.

These results compare as follows with literature data concerning the influence of plasmin on closure of macular holes. Only a single publication was found in which eyes with macular holes were initially treated with plasmin, or a combination of plasmin with gas, i.e. without surgical vitrectomy. Sakuma et al. 2005 (Eur J Ophthalmol 15, 787) reported that none of the 8 eyes treated with plasmin, or with plasmin combined with gas, led to closure of macular holes (see, e.g., “Conclusions” in Abstract), notwithstanding successful vitreous liquefaction and PVD. Closure of macular holes was achieved only after performing additional conventional surgical vitrectomy (see, e.g., Figure 2 in Sakuma et al. 2005). A reported benefit of plasmin in this procedure was the simplification and shortening of the surgical procedures. Another publication, by Trese et al. 2000 (Ophthalmology 107, 1607) reported on the closure of idiopathic macular holes. In contrast to the applicant’s work and Sakuma et al. 2005, the procedure, however, involved immediate classical surgical vitrectomy and gas injection following incubation with injected plasmin. The reported

benefit of plasmin concerned the reduction of operative time (see “Conclusions” in Abstract). *See*, Pakola Declaration, ¶28.

Three other publications (Margherio et al. 1998 – Ophthalmology 105, 1617; Chow et al. 1999 – Retina 19, 405; and Wu et al. 2007 – Am J Ophthalmol 144, 668) reported on the closure of traumatic macular holes. In all cases the procedure involved injection and incubation with plasmin immediately followed by conventional surgical vitrectomy and exchange of the vitreous fluid with gas or silicone oil. Moreover, Chow et al. 1999 reported the absence of a statistically significant effect of plasmin in achieving anatomic closure of traumatic macular holes (see page 407, left-hand column, last sentence of 4th full paragraph). *See*, Pakola Declaration, ¶29.

Dr. Pakola notes that the results of ThromboGenics’s clinical trials using microplasmin for vitreolysis show that microplasmin is unexpectedly safe and efficient in inducing vitreous liquefaction and PVD. As outlined above, this finding is not trivial and could, given the vast differences between microplasmin and plasmin, not be predicted from earlier similar work performed with plasmin. A further unexpected outcome of the clinical trials revealed that the process of vitreolysis by microplasmin must be different from that of vitreolysis by plasmin. This follows from the stunning finding that the action of microplasmin, but not the action of plasmin, is capable of inducing closure of macular holes in the absence of any surgical vitrectomy. *See*, Pakola Declaration, ¶30.

This unexpected beneficial clinical advantage of microplasmin over plasmin clearly supports applicant’s arguments about the differences between microplasmin and plasmin, as well as the argued unpredictability of substituting microplasmin for plasmin with a reasonable expectation of success (in terms of safety and efficacy). Moreover, all previously and currently presented *in vitro*, *ex vivo* and *in situ* data unequivocally illustrate that microplasmin and plasmin are two proteases not only with a different structure but also with different activity (e.g., different enzymatic activity, different binding and inactivation characterization and diffusion rates). Such differences are significant and render the effects of microplasmin unpredictable in the complex biologic system of both the vitreous and the vitreoretinal interface. *See*, Pakola Declaration, ¶31.

As previously stated, the biological activities of plasmin and microplasmin are not the same. Many proteases are capable of liquefying the vitreous and/or inducing PVD. And although both

plasmin and microplasmin are capable of effectuating both vitreous liquefaction and induction of PVD, the resulting liquefaction and PVD must differ between microplasmin and plasmin as only a difference can explain why microplasmin is efficient in inducing closure of macular holes in the absence of surgical vitrectomy and why plasmin is ineffective in this setting. *See*, Pakola Declaration, ¶32.

Hence, the overall conclusions are (i) that microplasmin and plasmin cannot be considered as art-recognized equivalents and (ii) that the current invention unexpectedly established microplasmin to be not only a suitable but moreover also an improved alternative to plasmin. This opinion is verified by Dr. Pakola. *See*, Pakola Declaration, ¶33.

*Based on Legal Precedent Claims Are Patentable*

Legal precedent dictates that, for a finding of obviousness, one must first identify a “lead compound” in the prior art that would have been selected as a starting point by a person of ordinary skill in the art (“POSITA”). One must establish that a POSITA would have modified the lead compound to arrive at patented compound because:

- There was a teaching, motivation, or suggestion in the prior art to make the modifications or
- “Obvious to try” based on the knowledge of a POSITA can be, in certain circumstances, an appropriate standard for determining invalidity under § 103

Once it is established that a POSITA would have begun with the prior art lead compound, the patent challenger then must establish that a POSITA would have made “the specific molecular modifications necessary to achieve the claimed invention.” *Takeda*, 492 F.3d at 1356. Evidence that a POSITA would not have made the modifications includes: (1) evidence of numerous possible modifications a POSITA could have made with no reason to make the particular modifications posited by the patent challenger (*Takeda*; cf. *Pfizer*); (2) teaching away from the particular modifications in the prior art (*Forest Labs.*); and (3) evidence that the modifications were technically difficult and unlikely to be attempted by a POSITA (*Forest Labs.*; cf. *Aventis*).

As stated in *KSR*, an invention may also be “obvious to try.” Factors that may support a finding of obvious to try include:

- Limited number of possibilities (*See, Pfizer v. Apotex*), where there were 53 FDA approved salts and the prior art identified 8 of those as the most preferable).
- Predictable results / Reasonable expectation of success
- Lack of technical difficulty in creating or purifying the compound

*See, Pfizer v. Apotex*, 480 F.3d 1348, 1367 (Fed. Cir. 2007).

In the instant case, at the time of the invention there was no motivation to substitute microplasmin for plasmin, absent the impermissible use of hindsight based upon applicant's own work. Contrary to the assertions in the Official action, there is a large genus of possible compounds to try for the desired activity. There is, for example, an unlimited number of potential modifications one could make to plasmin to find a new molecules. Moreover, there is a large family of proteins with serine protease activity (*e.g.*, chymotrypsin-like, subtilisin-like, alpha/beta hydrolases and signal peptidase clans). Further, due to the level of unpredictability in how structure affects activity, there was no reasonable likelihood of success. Persons of ordinary skill in the art ("POSITA") could not have predicted the effect of loss of kringle domains on biological activity. For example, POSITA would not have predicted how the differences in structure between plasmin and microplasmin would effect their degradation of fibrinogen by and result in differences in MMP-9 activity in human vitreous fluid. It could not have been predicted, for example, that loss of kringle 1 leads to loss of the feature to prevent bleeding. The unpredictability is discussed in more detail above and in the Pakola Declaration. These discussions are incorporated by reference herein. Moreover, contrary to what has actually been found, POSITA would have expected a decreased potency of microplasmin and expect high dose to be required when moving from plasmin to microplasmin. What would have predicted was shown to be in error. The art thus taught away from the claimed invention. *See, Pakola Declaration*, ¶19.

Based upon the applicable legal precedent, the claims of the instant application are not obvious and are patentable to applicant. Nor would the art have been combined as proposed in the Official Action.

Trese et al. disclose a vitrectomy method including plasmin-assisted induction of PVD followed by exchange of the vitreous humor by a saline solution. Microplasmin has been known

since December 1987. *See*, Wu et al. (PNAS 84, 8292-8295. Miniplasmin is known even longer. *See*, Powell & Castellino 1980 (J Biol Chem 255, 5329). Hence, at the time of the invention by Trese et al., there was a choice between plasmin and at least two plasmin variants for applying in the setting of pharmacologic vitreolysis. Yet, Trese et al. opted only for plasmin. Trese et al. thus in itself is teaching away from applying a truncated plasmin variant for the purpose of vitreolysis. This is not remedied by Collen et al. in further view of either Wu et al. or Tanaka et al.

Whereas Collen et al. teach the recombinant production of miniplasmin and microplasmin, these authors only contemplate the use of these recombinantly produced truncated plasmin variants for the purpose of treating thromboembolic disease. Moreover, Collen et al. leave fully open the issue of which of the truncated plasmin variants, miniplasmin or microplasmin, is preferred for treating thromboembolic disease. These inventors thus nowhere suggest or even hint at the possibility of using miniplasmin or microplasmin, let alone at a preferred possibility of using microplasmin, for the purpose of inducing vitreolysis. Inducing vitreolysis is not equivalent to treating thromboembolic disease and involves different mechanisms of action and in vivo concerns. Moreover, as mentioned above, Trese et al. already have opted for plasmin over the then already available miniplasmin and microplasmin. Collen et al. therefore does, in view of Trese et al., not provide any objective reason to start using a truncated plasmin variant for inducing vitreolysis.

As argued previously, Wu et al. do not compare fibrinolytic activities of microplasmin and plasmin. Proteolytic activities of both enzymes are compared using artificial colorogenic small-molecule substrates and casein. Casein is irrelevant in the settings of both thromboembolic diseases and vitreolysis. Furthermore, there is nowhere in Wu et al. a suggestion or hint to use microplasmin for the purpose of inducing vitreolysis. Thus, and at most, Wu et al. discloses a proteolytically active truncated variant of plasmin. These inventors, however, did not provide any evidence of equivalency of microplasmin with plasmin for use in any clinically relevant indication. Wu et al. therefore provide no single objective argument for using microplasmin instead of plasmin in the context of either Trese et al. (itself already teaching away from miniplasmin and microplasmin) or Collen et al., alone or in combination.

Tanaka et al. merely provides a review of then state-of-the-art pharmacological vitrectomy, comprising reporting on plasmin. No mentioning, however, of microplasmin, let alone of any

reasoned statement as to why microplasmin and plasmin would be equivalents or as to why microplasmin would be a suitable alternative to plasmin. Therefore Tanaka et al. does not add anything substantial to the disclosures of Trese et al. alone or in view of Collen et al.

The rejections of record thus are believed to be in error.

Conclusion


In view of the above arguments, applicant believes the pending application is in condition for allowance. Further and favorable action is respectfully requested.

The Commissioner is hereby authorized to charge Deposit Account 08-0219 the 3-month extension of time fee of \$525.00.

Applicant believes no other fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 08-0219, under Order No. 0113476.00122US1 from which the undersigned is authorized to draw.

Respectfully submitted,

Dated: September 26, 2008

  
Donna M. Meuth  
Registration No.: 36,607  
Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP  
60 State Street  
Boston, Massachusetts 02109  
(617) 526-6000 (telephone)  
(617) 526-5000 (facsimile)